Defining the decision problem
|
The scope developed by NICE
|
4.2.4 to 4.2.6
|
Comparator(s)
|
As listed in the scope developed by NICE
|
2.2.12 to 2.2.16, 4.2.6, 4.2.13
|
Perspective on outcomes
|
All health effects, whether for patients or, when relevant, carers
|
4.2.7, 4.2.8
|
Perspective on costs
|
NHS and personal social services (PSS)
|
4.2.9 and 4.2.10
|
Types of economic evaluation
|
Cost-utility analysis with fully incremental analysis
Cost-comparison analysis
|
4.2.14 to 4.2.17
4.2.18 to 4.2.21
|
Time horizon
|
Long enough to reflect all important differences in costs or outcomes between the technologies being compared
|
4.2.22 to 4.2.25
|
Synthesis of evidence on health effects
|
Based on systematic review
|
3.4
|
Measuring and valuing health effects*
|
Health effects should be expressed in quality-adjusted life years (QALYs). The EQ‑5D is the preferred measure of health-related quality of life in adults
|
4.3.1, 4.3.6
|
Source of data for measurement of health-related quality of life*
|
Reported directly by patients or carers, or both
|
4.3.3
|
Source of preference data for valuation of changes in health-related quality of life*
|
Representative sample of the UK population
|
4.3.4
|
Equity considerations*
|
An additional QALY has the same weight regardless of the other characteristics of the individuals receiving the health benefit, except in specific circumstances
|
6.2.10
|
Evidence on resource use and costs
|
Costs should relate to NHS and PSS resources and should be valued using the prices relevant to the NHS and PSS
|
4.4.1
|
Discounting
|
The same annual rate for both costs and health effects (currently 3.5%)
|
4.5.1
|